Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmaust Limited ( (AU:NUZ) ) has provided an update.
Neurizon Therapeutics has issued 10,000,000 fully paid ordinary shares to Obsidian Global GP, LLC under a previously approved convertible note facility, following shareholder approval at a recent general meeting. The company confirmed the shares were issued without a prospectus under the Corporations Act disclosure exemptions, stated it is up to date with its financial reporting and continuous disclosure obligations, and advised that there is no excluded information, helping to provide regulatory clarity and maintain investor confidence around the capital raising.
Neurizon also highlighted the availability of its dedicated Investor Hub, designed to centralise communication with shareholders through Q&A, feedback, and video summaries of key announcements. This initiative supports greater transparency and engagement with investors as the company advances its clinical programs and deploys new capital from the share issuance to fund its neurodegenerative disease pipeline.
The most recent analyst rating on (AU:NUZ) stock is a Hold with a A$0.08 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Its lead drug candidate, NUZ-001, is being developed for amyotrophic lateral sclerosis (ALS), with a strategy to accelerate access to effective ALS therapies while assessing broader applications in complex neural disorders.
Average Trading Volume: 532,927
Technical Sentiment Signal: Sell
Current Market Cap: A$66.8M
See more insights into NUZ stock on TipRanks’ Stock Analysis page.